Source: ‘Breakthrough’ Alzheimer’s drugs unlikely to benefit patients, report suggests – BBC News
Influential analysis has concluded that “breakthrough” Alzheimer’s drugs are unlikely to benefit patients.
Researchers said the impact was “well below” what was needed to make a difference to dementia patients’ lives.
However, their report has also provoked a vicious backlash from equally esteemed scientists who label it as fundamentally flawed.
At the moment the NHS won’t pay for these drugs and an 18-month course would set you back a hefty £90,000 privately. They would be unaffordable for most so even if you had the money, are they worth paying for?
Click here to read more: ‘Breakthrough’ Alzheimer’s drugs unlikely to benefit patients, report suggests – BBC News
Categories: News